Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Clinical Trial of Immunogenicity of ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a Population Aged 6 to 23 Months

NCT05935176 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT05935176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05935176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Clinical Trial of Immunogenicity of ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a Population Aged 6 to 23 Months
Lead sponsor
CanSino Biologics Inc.
Phase
Phase 4
Overall status
Active, not recruiting
Start date
September 20, 2023
Completion date
July 15, 2026
Enrollment
660 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epidemic meningitis